儿童末期扩张性心肌病的可逆肺动脉带化:一种替代策略
1Department of Pediatric Cardiac Surgery, U N Mehta Institute of Cardiology & Research Centre, Ahmedabad, 380004 Gujarat India.
Indian journal of thoracic and cardiovascular surgery
|February 12, 2026
概括
可逆肺动脉带带 (rPAB) 为患有左心室扩张心肌病 (LV-DCM) 的儿科患者提供了一个有前途的替代疗法,当其他治疗方法不适合时. 这种方法解决了心脏移植和机械支持这一高风险群体的局限性.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 心脏外科手术 心脏外科手术
- 心肌病研究研究 心肌病研究
背景情况:
- 在儿童中,左心室扩张性心肌病 (LV-DCM) 具有显著的死亡风险,特别是当医疗管理失败时.
- 目前的治疗选择,如心脏移植和机械循环支持,受到供体器官稀缺和设备相关风险的限制.
研究的目的:
- 概述可逆肺动脉带化 (rPAB) 作为儿科LV-DCM的替代疗法.
- 突出rPAB的潜力,作为儿科心脏护理的重大进展.
主要方法:
- 本文回顾了关于rPAB在儿科LV-DCM中的应用现有的文献和临床数据.
- 重点是了解rPAB的机制,结果和适用性.
主要成果:
- 对于患有耐火性LV-DCM的儿科患者来说,rPAB是一个可行的治疗选择.
- 它提供了一个潜在的解决方案,当传统干预措施是禁忌或不可用的.
结论:
- 可逆肺动脉带纹 (rPAB) 显示出相当大的希望,作为儿科LV-DCM的创新治疗策略.
- 进一步的研究和rPAB的临床应用可以显著改善这一具有挑战性的患者群体的结果.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
589
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
589
Band Theory
17.3K
When two or more atoms come together to form a molecule, their atomic orbitals combine and molecular orbitals of distinct energies result. In a solid, there are a large number of atoms, and therefore a large number of atomic orbitals that may be combined into molecular orbitals. These groups of molecular orbitals are so closely placed together to form continuous regions of energies, known as the bands.
The energy difference between these bands is known as the band gap.
Conductor, Semiconductor,...
The energy difference between these bands is known as the band gap.
Conductor, Semiconductor,...
17.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
526
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
526
Cardiomyopathy IV: Restrictive Cardiomyopathy
587
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
587
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
625
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
625
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
484
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
484


